Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary

Pathol Oncol Res. 2024 Mar 21:30:1611758. doi: 10.3389/pore.2024.1611758. eCollection 2024.

Authors

Peter Batar¹, Hussain Alizadeh², Gyorgy Rokszin³, Zsolt Abonyi-Toth^{3

4}, Judit Demeter⁵

Affiliations

¹ Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
² 1st Department of Medicine, Division of Haematology, Clinical Center, Medical School, University of Pecs, Pecs, Hungary.
³ RxTarget Ltd., Szolnok, Hungary.
⁴ Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary.
⁵ Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

Abstract

[This corrects the article DOI: 10.3389/pore.2024.1611497.].

Keywords: chronic myeloid leukemia; overall survival; real-word evidence; treatment outcome; tyrosine kinase inhibitors.

Copyright © 2024 Batar, Alizadeh, Rokszin, Abonyi-Toth and Demeter.

Publication types

Published Erratum